Quartesian LLC Executes Multi-Year Enterprise Agreement with Medrio, Securing Access to Innovative eClinical Functionality and Support Services

prweb | April 17, 2019

Quartesian LLC Executes Multi-Year Enterprise Agreement with Medrio, Securing Access to Innovative eClinical Functionality and Support Services
Quartesian LLC, a full-service contract research organization (CRO) providing data management, biostatistics, and other services to clinical trial sponsors, has entered into a multi-year agreement with Medrio, a leading provider of eClinical technology for clinical trials. The agreement will enable Quartesian, a member of Medrio’s Certified Partner Program, to leverage the full range of Medrio’s products including EDC, eConsent, ePRO, and Direct Data Capture (DDC) to support their clients in the emerging growth biotech and pharma spaces. “The Medrio system will be a key asset in our efforts to compress timelines, reduce costs, and improve data cleanliness in our clinical trials, enabling us to deliver top-quality services to our clients and free up resources to work more productively,” commented Stephen Boccardo, Senior Vice President of Business Development and Commercial Strategy at Quartesian. “We fully expect our partnership with Medrio over the course of this agreement to be fulfilling and mutually beneficial.” The agreement also enables Quartesian, as a member of the Medrio Partner Program, to access a wide range of exclusive support services geared toward facilitating new connections between CROs and study sponsors. “We’re excited to announce this multi-year partnership between Quartesian and Medrio,” commented Steve Geffon, Chief Commercial Officer at Medrio. “By leveraging the functionality of Medrio’s eClinical platform and the support services of the Certified Partner Program, we expect Quartesian to be successful in exceeding their corporate objectives.”

Spotlight

Continuous band sealing machine suits for Pharmaceuticals, chemical industries, dairy, cosmetic, food & groceries, seed processing units, automobile spare parts, electronic spare and online and offline Packaging of respective product range.

Related News

CNS Pharmaceuticals Announces US Drug Manufacturing Milestones

CNS Pharmaceuticals | September 03, 2020

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, today provides an update on progress for the U.S. manufacturing of Berubicin, the Company's lead drug candidate, in preparation for upcoming clinical trials. As previously announced, the Company implemented a dual-track drug product manufacturing strategy and engaged U.S.-based Pharmaceutics International, Inc. ("Pii") and Italy-based BSP Pharmaceuticals S.p.A. ("BSP") for the production of Berubicin. By engaging two separate manufacturers on two separate continents, CNS expects to mitigate COVID-19-related delay risks, diversify its supply chain and provide for localized availability of Berubicin.

Read More

Lannett Signs Agreement To Be Exclusive Distributor Of Generic Flovent® Diskus®

Prnewswire | August 17, 2020

Lannett Company, Inc. today announced that it has entered into an exclusive U.S. distribution agreement for the therapeutically equivalent generic of Flovent® Diskus® (Fluticasone Propionate Powder Inhaler) of Respirent Pharmaceuticals Co. Ltd. According to the Orange Book, all patents covering Flovent Diskus have expired. U.S. sales of Flovent Diskus, which have been increasing in recent years, were $94 million for the 12 months ending June, 2020 according to IQVIA, although actual generic market values are expected to be lower. The company also said its previously announced exclusive U.S. distribution agreement with Respirent for the therapeutically equivalent generic of ADVAIR DISKUS® (Fluticasone Propionate – Salmeterol Xinafoate Powder Inhaler) has been extended from 10 years to 12 years. The term of the agreement commences upon distribution of the product.

Read More

Hemogenyx Pharmaceuticals plc signed Biological Investigation and Material Supply Agreement with Eli Lilly

Hemogenyx Pharmaceuticals | July 14, 2020

On 26 June 2020 the Company announced a Development Agreement with a global pharmaceutical company ("GlobalCo"). GlobalCo has now consented to the use of its name in the announcement, an updated version of which is shown below. Hemogenyx Pharmaceuticals plc is pleased to announce that it has signed a Biological Investigation and Material Supply Agreement ("Agreement") with Eli Lilly and Company ("Lilly"), a leading global pharmaceutical company engaged in the research, development, manufacture and marketing of human pharmaceutical and veterinary products. Under the Agreement, Lilly will supply the Company with certain biological materials and related confidential information in order for Company to perform research and development activities aimed at the discovery and validation of novel materials ("Materials") to be used for the treatment of systemic lupus erythematosus ("Lupus") and possibly other autoimmune diseases.

Read More

Spotlight

Continuous band sealing machine suits for Pharmaceuticals, chemical industries, dairy, cosmetic, food & groceries, seed processing units, automobile spare parts, electronic spare and online and offline Packaging of respective product range.